Gionata Fiorino
YOU?
Author Swipe
View article: International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements
International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements Open
Background Reproduction is a fundamental aspect of life. This study aimed to provide an international overview of gastroenterologists' approaches to managing inflammatory bowel disease (IBD) during preconception, pregnancy, lactation, and …
View article: When AI speaks like a specialist: ChatGPT-4 in the management of inflammatory bowel disease
When AI speaks like a specialist: ChatGPT-4 in the management of inflammatory bowel disease Open
Background Artificial intelligence (AI) is gaining traction in healthcare, especially for patients’ education. Inflammatory bowel diseases (IBD) require continuous engagement, yet the quality of online information accessed by patients is i…
View article: Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study
Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study Open
Background Few data are available on the impact of primary sclerosing cholangitis (PSC) on inflammatory bowel disease (IBD). Objective We conducted a retrospective study using TriNetX to compare the outcomes of patients with IBD and those …
View article: Patient and First‐Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey
Patient and First‐Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey Open
Background and Objective While significant advances have been made in identifying biomarkers for predicting inflammatory bowel disease (IBD) onset, little is known about the willingness of at‐risk individuals to undergo predictive testing …
View article: Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review
Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review Open
Depression, anxiety, and perceived stress are common comorbidities in patients with inflammatory bowel disease (IBD) and may negatively influence the disease course. Likewise, severe IBD may contribute to the development or worsening of ps…
View article: Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study Open
Background: Colonoscopy is crucial for diagnosing and monitoring inflammatory bowel disease (IBD), assessing disease activity, and detecting dysplasia. However, patient adherence to surveillance remains suboptimal due to discomfort, anxiet…
View article: Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease
Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease Open
Data indicate that earlier initiation of anti-tumor necrosis factor alpha (anti-TNF-α) biologic medicines may prevent progression to irreversible bowel damage and improve outcomes for patients with inflammatory bowel disease (IBD), particu…
View article: Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment Open
Biologic therapies have revolutionized Crohn's disease (CD) management, but their high costs pose a significant barrier to access. Biosimilars can provide increased access to treatment because of significant cost‐savings. Ustekinumab is a …
View article: Dual Therapy in Inflammatory Bowel Disease
Dual Therapy in Inflammatory Bowel Disease Open
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic and complex autoimmune conditions. Despite the advancements in biologics and small molecules, the therapeutic ceiling persists, pos…
View article: Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference Open
Background Fecal microbiota transplantation (FMT) is emerging as a potential treatment modality for individuals living with inflammatory bowel disease (IBD). Despite its promise, the effectiveness of FMT for treating IBD, particularly for …
View article: Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials Open
ACT did not offer clinical benefit in patients with rheumatological IMIDs and resulted in higher rate adverse events in rheumatoid arthritis. ACT may offer clinical benefit without a clear safety signal in patients with IBD, but further tr…
View article: Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence
Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence Open
Various extrinsic and intrinsic factors such as drug exposures, antibiotic treatments, smoking, lifestyle, genetics, immune responses, and the gut microbiome characterize ulcerative colitis and Crohn's disease, collectively called inflamma…
View article: Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis—The OPTIMISE Study
Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis—The OPTIMISE Study Open
Background: Current management of mild-to-moderate ulcerative colitis (UC) involves monitoring clinical markers of disease activity, such as stool frequency (SF) and rectal bleeding (RB), and adjusting treatment accordingly. Our aim was to…
View article: The Role of Fecal Microbiota Transplantation in IBD
The Role of Fecal Microbiota Transplantation in IBD Open
Gut microbiota dysbiosis has a critical role in the pathogenesis of inflammatory bowel diseases, prompting the exploration of novel therapeutic approaches like fecal microbiota transplantation, which involves the transfer of fecal microbio…
View article: Inflammatory Bowel Disease and Colorectal Cancer
Inflammatory Bowel Disease and Colorectal Cancer Open
Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn’s disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrat…
View article: Small Bowel Cancer in Crohn’s Disease
Small Bowel Cancer in Crohn’s Disease Open
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) that frequently affects the small bowel. Individuals diagnosed with CD are at increased risk of developing bowel cancer compared to the general population. Small bowel canc…
View article: Inflammatory Bowel Disease and Colorectal Cancer
Inflammatory Bowel Disease and Colorectal Cancer Open
Patients with inflammatory bowel diseases (IBD), including both ulcerative colitis (UC) and Crohn's disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, inte…
View article: An international multicentre study of <scp>SwiTching</scp> from Intravenous to subcutaneous <scp>inflixiMab</scp> and <scp>vEdolizumab</scp> in inflammatory bowel diseases: The <scp>TIME</scp> study
An international multicentre study of <span>SwiTching</span> from Intravenous to subcutaneous <span>inflixiMab</span> and <span>vEdolizumab</span> in inflammatory bowel diseases: The <span>TIME</span> study Open
Background and Aims Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV)…
View article: Endoscopic Treatment Approaches for Inflammatory Bowel Diseases: Old Friends and New Weapons
Endoscopic Treatment Approaches for Inflammatory Bowel Diseases: Old Friends and New Weapons Open
Inflammatory Bowel Diseases (IBD) still represent a significant medical challenge. The course of IBD is characterized by the development of fibrotic, inflammatory, or dysplastic lesions over time. Recent advancements in operative endoscopy…
View article: Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases
Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases Open
The incidence and prevalence of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are rapidly increasing. Currently, colonoscopy is the gold standard for diagnosing and monitoring the course of IBD. Howev…
View article: ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment Open
View article: ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment Open
This article is the second in a series of two publications on the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s disease. The first article covers medical management; the present arti…
View article: Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study
Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study Open
None.
View article: Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment Open
Background Inflammatory bowel disease requires long-term treatment; therefore, understanding patient preferences is important in aiding informed treatment decision making. This study explored patients’ preferences for treatment attributes …
View article: Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy
Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy Open
Background: Vedolizumab (VDZ) and infliximab are used to treat moderate to severe ulcerative colitis (UC). The choice of the drug to use at first-line is often based on a combination of clinical and economic factors. The cost of treatment …
View article: Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy
Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy Open
Background This real-world analysis evaluated iron therapy supplementation in inflammatory bowel disease patients with iron-deficiency anemia, considering disease progression and healthcare resource consumption. Methods A retrospective obs…
View article: Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study
Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study Open
Background Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of th…
View article: Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus Open
Background and Aims Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was …
View article: Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) Open
View article: The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease
The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease Open
Inflammatory activity in patients with CD is associated with changes in CP volume and permeability, thus supporting the hypothesis that intestinal inflammation could affect the brain through the modulation of CP vascular barrier also in hu…